Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 15:8:F1000 Faculty Rev-294.
doi: 10.12688/f1000research.16686.1. eCollection 2019.

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma

Pierre Feugier  1   2 , Lauriane Filliatre-Clement  1
Affiliations
Review

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma

Pierre Feugier et al. F1000Res. .

Abstract

Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma. Twenty years ago, FL was considered an indolent lymphoma with a long survival time but without a high rate of complete remission with chemotherapies. The use of rituximab has improved the response and survival of patients with this lymphoma. More recently, development of biological knowledge and use of targeted drugs have offered new perspectives, including improvement of response rates and survival with chemo-free treatment strategies. In 2019, patients have a 10-year overall survival probability of over 70%. Histological transformation to more aggressive lymphoma and treatment relapses remain a medical challenge, especially for patients relapsing within two years. This article will review the recent advances in the treatment of FL. As the use of new drugs is directly related to the development of biological aspects, we will first summarize recent advances in biological aspects of FL.

Keywords: first line; follicular lymphoma; treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PF received reimbursements and fees in the past 5 years for Roche, Gilead, Janssen, Abbvie and Celgene companies. LFC has no competing interests.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Lackraj T, Goswami R, Kridel R: Pathogenesis of follicular lymphoma. Best Pract Res Clin Haematol. 2018;31(1):2–14. 10.1016/j.beha.2017.10.006 - DOI - PubMed

    2. F1000 Recommendation

    1. Roulland S, Kelly RS, Morgado E, et al. : t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32(13):1347–55. 10.1200/JCO.2013.52.8190 - DOI - PubMed

    2. F1000 Recommendation

    1. Correia C, Schneider PA, Dai H, et al. : BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125(4):658–67. 10.1182/blood-2014-04-571786 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Farinha P, Masoudi H, Skinnider BF, et al. : Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169–74. 10.1182/blood-2005-04-1565 - DOI - PubMed

    2. F1000 Recommendation

    1. Canioni D, Salles G, Mounier N, et al. : High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial. JCO. 2008;26(3):440–6. 10.1200/JCO.2007.12.8298 - DOI - PubMed

MeSH terms